Novalis Biotech

Novalis Biotech operates as an early-stage venture capital firm, strategically investing in life sciences companies that develop enabling technologies within the healthcare sector. Their focus spans digital health solutions, advanced diagnostics, and innovative life sciences tools. The firm provides capital and expertise to cultivate the growth of its portfolio companies, identifying promising intellectual property and business models for biomedical advancement.

Founded in 2018 by Prof. Wim Van Criekinge and Jan Van den Berghe, the firm emerged from a shared understanding of the critical need for specialized early-stage capital and support for nascent technology-biology ventures. The founders leveraged their deep expertise in life sciences, aiming to bridge the gap between scientific discovery and commercial application.

Novalis Biotech targets innovative, early-stage companies and entrepreneurial teams creating disruptive solutions across the life sciences industry. The firm's overarching vision is to accelerate the development and market integration of groundbreaking technologies designed to fundamentally improve human health. Through strategic investments and active guidance, Novalis Biotech endeavors to significantly shape healthcare's future.